About OncoSynergy
OncoSynergy is a company based in San Francisco (United States) founded in 2011 was acquired by DanDrit in April 2016. OncoSynergy has raised $33.32 million across 8 funding rounds from investors including HHS, National Cancer Institute and KICC. The company has 3 employees as of December 31, 2021. OncoSynergy offers products and services including OS2966 and Therapeutic Platforms. OncoSynergy operates in a competitive market with competitors including Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.
- Headquarter San Francisco, United States
- Employees 3 as on 31 Dec, 2021
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oncosynergy, Inc.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of OncoSynergy
OncoSynergy offers a comprehensive portfolio of products and services, including OS2966 and Therapeutic Platforms.
Antibody that blocks receptors to inhibit cancer growth and resistance
Platforms for developing treatments against various solid and hematological cancers
People of OncoSynergy
Unlock access to complete
Unlock access to complete
Funding Insights of OncoSynergy
OncoSynergy has successfully raised a total of $33.32M across 8 strategic funding rounds. The most recent funding activity was a Series A round of $6.61 million completed in May 2026. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in OncoSynergy
OncoSynergy has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include HHS, National Cancer Institute and KICC.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital services for biotech, IT, and innovative sectors in Connecticut.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Cancer research is conducted and supported by the institute.
|
Locked | Locked | Locked |
Investor details for OncoSynergy
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by OncoSynergy
Investment portfolio details for OncoSynergy
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - OncoSynergy
Detailed financials for OncoSynergy
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncosynergy Comparisons
Peer comparison for OncoSynergy
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of OncoSynergy
OncoSynergy operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Harbour BioMed, Xilio Therapeutics, Zymeworks, Lassen Therapeutics and Ambrx, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Antibody therapeutics are developed for immunology and oncology diseases.
|
|
| Locked | Locked | Locked |
Tumor-selective immunotherapies for cancer treatment are developed.
|
|
| Locked | Locked | Locked |
Bi-specific antibodies and antibody-drug conjugates are developed for cancer treatment.
|
|
| Locked | Locked | Locked |
Biotherapeutics targeting cancer via interleukin-11 are developed.
|
|
| Locked | Locked | Locked |
Antibody-drug conjugates are developed for cancers and metabolic disorders.
|
|
| Locked | Locked | Locked |
Antibody therapeutics for anti-cancer immune responses are developed.
|
Detailed competitors of OncoSynergy
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncosynergy
Complete news archive for OncoSynergy
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about OncoSynergy
OncoSynergy was founded in 2011 and raised its 1st funding round 7 years after it was founded.
OncoSynergy is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
OncoSynergy is a funded company, having raised a total of $33.32M across 8 funding rounds to date.
As of Dec 31, 2021, the latest employee count at OncoSynergy is 3.
OncoSynergy was founded in 2011 and is based in San Francisco, United States. Inhibitors targeting resistance mechanisms in cancer are developed by the company within the oncology sector. Multiple hallmarks of cancer progression are addressed, with efficacy shown in monotherapy and combinations. The lead program, OS2966, consists of a therapeutic antibody that blocks a cell surface receptor, aimed at treating glioblastoma, ovarian cancer, pancreatic cancer, and malignant meningioma.
OncoSynergy's top competitors include Xilio Therapeutics, Ambrx and Harbour BioMed.
OncoSynergy offers OS2966 and Therapeutic Platforms.
OncoSynergy has 6 investors. Key investors include HHS, National Cancer Institute, KICC, Connecticut Innovations, and Navation.